

Global Kinetics Corporation Appoints Greg Barrett As Independent Director to its Board of Directors

PORTSMOUTH, NH USA, and MELBOURNE, Australia, April 2, 2019

Global Kinetics Pty Ltd., a medical device company focused on the development and commercialization of the first FDA-cleared and CE-marked wearable watch for the objective treatment and management of Parkinson's disease, called the Personal KinetiGraph® (PKG®), today announced the appointment of Gregory Barrett, a distinguished medical device industry expert, as an independent director to its Board of Directors.

"We are pleased and excited to welcome Mr. Barrett to our Board," said John Schellhorn, CEO of Global Kinetics Corporation. "With his success scaling multiple medical device companies and his proven leadership qualities, Greg will be an invaluable voice on our Board of Directors as GKC continues to bring technologies to market which improve the lives of patients with Parkinson's disease."

Mr. Barrett has over 40 years of medical device experience, including in the fields of spine, radiology, oncology, gastroenterology, urology, cardiology, and cardiovascular surgery. Previously he served as president and CEO at DFINE Inc. – where he restructured the company and negotiated its sale to Merit Medical. Prior to Dfine, Mr. Barrett was Chairman, President, and CEO of BÂRRX Medical. BARRX was sold to Covidien in January 2012. Previous to joining BÂRRX Medical, Mr. Barrett served as President and CEO of ACMI Corporation, which was acquired by Gyrus Medical and subsequently by Olympus Medical.

Currently, Mr. Barrett sits on the Board of Directors for BTG PLC, Cutera Inc., and Aqua Medical. He holds a B.B.A. in Marketing from University of Texas: Austin.

About Global Kinetics Pty Ltd.

Global Kinetics Pty Ltd. is committed to improving the lives of those with Parkinson's disease with advanced medical technologies. The company was formed in 2007 to commercialize its lead product, the Personal KinetiGraph (PKG). The PKG enables the precise monitoring, quantification, and reporting of movement symptoms in Parkinson's. To date, Global Kinetics has supported clinical decisions for doctors who have treated more than 40,000 patients with Parkinson's Disease, generating more than 6,000,000 hours of clinical data from our FDA-cleared, CE-marked PKG wearable device. Global Kinetics, a privately held company, is headquartered in Melbourne, Australia with offices in London, UK, Minneapolis, MN, and Portsmouth, NH, USA.

For more information, visit: www.globalkineticscorporation.com

Follow our LinkedIn updates: <https://www.linkedin.com/company/globalkineticscorp>

Media Contact

Lazar Partners

Chantal Beaudry / Amy Feldman

+1 (646) 871-8480 / +1 (212) 867-1779

GKC@lazarpartners.com